X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11377) 11377
Book Review (3476) 3476
Publication (1093) 1093
Newsletter (281) 281
Book Chapter (75) 75
Conference Proceeding (22) 22
Newspaper Article (22) 22
Dissertation (7) 7
Book / eBook (2) 2
Magazine Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9684) 9684
humans (7419) 7419
animals (4435) 4435
oncology (3731) 3731
tyrosine (2931) 2931
male (2921) 2921
cancer (2806) 2806
female (2695) 2695
pharmacology & pharmacy (2675) 2675
tyrosine kinase inhibitor (2539) 2539
mice (1858) 1858
antineoplastic agents - therapeutic use (1742) 1742
middle aged (1454) 1454
research (1449) 1449
care and treatment (1368) 1368
antineoplastic agents - pharmacology (1335) 1335
adult (1298) 1298
rats (1293) 1293
analysis (1276) 1276
tyrosine kinase inhibitors (1259) 1259
aged (1248) 1248
chemotherapy (1209) 1209
protein kinase inhibitors - therapeutic use (1206) 1206
tyrosine kinase (1145) 1145
cell line, tumor (1126) 1126
protein kinase inhibitors - pharmacology (1080) 1080
protein-tyrosine kinases - antagonists & inhibitors (1058) 1058
pharmacokinetics (1049) 1049
kinases (1046) 1046
biochemistry & molecular biology (1005) 1005
tumors (981) 981
medicine & public health (966) 966
neoplasms - drug therapy (960) 960
dose-response relationship, drug (933) 933
mutation (925) 925
treatment outcome (900) 900
drug therapy (878) 878
health aspects (870) 870
cell lung-cancer (864) 864
growth-factor receptor (858) 858
endothelial growth-factor (853) 853
proteins (813) 813
article (803) 803
angiogenesis (800) 800
chemistry, medicinal (798) 798
expression (790) 790
hematology (779) 779
imatinib mesylate (764) 764
lung neoplasms - drug therapy (763) 763
therapy (763) 763
protein-tyrosine kinase (762) 762
antineoplastic agents - pharmacokinetics (756) 756
phosphorylation (756) 756
metastasis (731) 731
antineoplastic agents (722) 722
phenols (707) 707
signal transduction - drug effects (699) 699
signal transduction (695) 695
gefitinib (692) 692
antineoplastic agents - adverse effects (689) 689
antimitotic agents (682) 682
carcinoma, non-small-cell lung - drug therapy (676) 676
vascular endothelial growth factor (670) 670
chronic myeloid-leukemia (650) 650
clinical trials (644) 644
imatinib (639) 639
receptor, epidermal growth factor - antagonists & inhibitors (638) 638
in-vivo (633) 633
pharmacology/toxicology (633) 633
epidermal growth factor (630) 630
neurosciences (625) 625
cell biology (618) 618
apoptosis (613) 613
clinical trials as topic (606) 606
antineoplastic agents - administration & dosage (599) 599
antitumor-activity (589) 589
pharmacology (586) 586
leukemia (583) 583
in-vitro (576) 576
resistance (564) 564
phase-ii trial (559) 559
sunitinib (556) 556
protein kinase inhibitors - pharmacokinetics (551) 551
erlotinib (547) 547
physiological aspects (546) 546
cell proliferation - drug effects (537) 537
cells (536) 536
lung cancer (532) 532
pyrimidines - therapeutic use (515) 515
inhibitors (514) 514
egfr (500) 500
inhibitor (494) 494
medicine (493) 493
medical research (491) 491
antineoplastic combined chemotherapy protocols - therapeutic use (488) 488
aged, 80 and over (487) 487
lung cancer, non-small cell (486) 486
genetic aspects (484) 484
cancer research (481) 481
activation (474) 474
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11665) 11665
French (28) 28
German (23) 23
Japanese (7) 7
Chinese (6) 6
Russian (6) 6
Italian (5) 5
Korean (2) 2
Spanish (2) 2
Danish (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 9/2011, Volume 50, Issue 9, pp. 551 - 603
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Cabozantinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid... 
pharmacokinetics | CYP2C8 | drug–drug interaction | CYP3A4 | cabozantinib | drug-drug interaction | XL184 | ERYTHROMYCIN | SUNITINIB | PHARMACOLOGY & PHARMACY | SORAFENIB | 6-BETA-HYDROXYCORTISOL | Rifampin - pharmacokinetics | Area Under Curve | Ketoconazole - administration & dosage | Humans | Microsomes, Liver - metabolism | Half-Life | Pyridines - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Anilides - pharmacokinetics | Antineoplastic Agents - administration & dosage | Thiazolidinediones - pharmacokinetics | Hypoglycemic Agents - blood | Drug Interactions | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Microsomes, Liver - enzymology | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ketoconazole - pharmacokinetics | Anilides - blood | Cytochrome P-450 CYP3A Inducers - administration & dosage | Pyridines - blood | Anilides - administration & dosage | Antineoplastic Agents - blood | Thiazolidinediones - blood | Dosage and administration | Ketoconazole | Pharmacokinetics | Rifampin | Analysis | Drug interactions | Plasma | Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2014, Volume 74, Issue 1, pp. 95 - 115
This study evaluated the preclinical pharmacokinetics (PK) and disposition of Fruquintinib (HMPL-013), a small molecule vascular endothelial growth factor... 
Fruquintinib | Medicine & Public Health | Disposition | Oncology | Cancer Research | HMPL-013 | Pharmacology/Toxicology | Pharmacokinetics | Allometric scaling | Modeling | HALF-LIFE | NONSPECIFIC-BINDING | CLEARANCE | FACTOR RECEPTORS | PROTEIN-BINDING | IN-VITRO | POTENT | ONCOLOGY | DRUGS | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | ENDOTHELIAL GROWTH-FACTOR | Inactivation, Metabolic | Drugs, Investigational - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Bile - chemistry | Humans | Microsomes, Liver - metabolism | Drugs, Investigational - pharmacokinetics | Cytochrome P-450 Enzyme System - metabolism | Quinazolines - pharmacokinetics | Benzofurans - administration & dosage | Benzofurans - pharmacology | Biological Availability | Male | Drugs, Investigational - metabolism | Intestinal Absorption | Benzofurans - pharmacokinetics | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Quinazolines - metabolism | Microsomes, Liver - drug effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Quinazolines - administration & dosage | Microsomes, Liver - enzymology | Drug Evaluation, Preclinical | Caco-2 Cells | Protein Kinase Inhibitors - pharmacokinetics | Food-Drug Interactions | Cells, Cultured | Angiogenesis Inhibitors - pharmacology | Angiogenesis Inhibitors - pharmacokinetics | Random Allocation | Protein Kinase Inhibitors - administration & dosage | Angiogenesis Inhibitors - metabolism | Animals | Models, Biological | Drugs, Investigational - administration & dosage | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Benzofurans - metabolism | Protein Kinase Inhibitors - metabolism | Physiological aspects | Permeability | Metabolites | Vascular endothelial growth factor | Gastrointestinal system | Protein binding | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2016, Volume 78, Issue 1, pp. 63 - 71
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2019, Volume 59, Issue 8, pp. 1099 - 1109
Osimertinib is a potent, third‐generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI)... 
non–small cell lung cancer | P‐glycoprotein | drug interaction | fexofenadine | osimertinib | P-glycoprotein | non-small cell lung cancer | PERMEABILITY | TRANSPORTERS | CHEMOTHERAPY